All posts by Synowledge

Synowledge Achieves Gold Partner Status in the Oracle PartnerNetwork (OPN)

Stamford, CT, October 8, 2010 – Synowledge LLC, a market leader in drug safety and pharmacovigilance services and IT solutions for organizations of all sizes announced that it has achieved Gold Partner status in the Oracle PartnerNetwork (OPN). By attaining Gold Level membership, Oracle has recognized Synowledge for its capability and commitment to design, deliver and support Oracle-based technology solutions customized to customers’ specialized needs.

With its Gold status, Synowledge is eligible to access the entire Oracle technology product stack and can resell Oracle Technology products.  This is a mutually beneficial partnership that allows Synowledge to tap into Oracle’s demonstrated strength in Oracle-based technologies, while providing services and solutions on Oracle applications. Customers will benefit from our combined strengths to increase their technical capabilities, increase efficiencies and reduce costs. To find out more, please visit http://www.synowledge.com/its.html.

“Synowledge is proud to have the Oracle Gold Partnership and we plan to utilize the benefits to further provide targeted, customized IT services for our customers. With access to all technology products in the Oracle line, Synowledge can now focus aggressively on increasing the potential business opportunities and expanding our solution offerings for existing customers,“ said David Ingraham, Director, Sales & Marketing.

About Oracle PartnerNetwork

Oracle PartnerNetwork (OPN) Specialized is the latest version of Oracle’s partner program that provides partners with tools to better develop, sell and implement Oracle solutions. OPN Specialized offers resources to train and support specialized knowledge of Oracle products and solutions and has evolved to recognize Oracle’s growing product portfolio, partner base and business opportunity. Key to the latest enhancements to OPN is the ability for partners to differentiate through Specializations.

About Synowledge

Synowledge is a global provider of IT solutions to small, mid and large-size organizations. Our comprehensive outsourcing solutions combine the unique strengths of both onshore and offshore services to meet all our clients’ needs. Our core team members have worked with some of the largest organizations in the world and bring more than 20 years of experience to the table. We have our headquarters located in Stamford CT, USA and additional offices in the United Kingdom, Columbus Ohio, and Bangalore, India. For more information, please visit www.Synowledge.com

###

Synowledge to Participate in Pacific Drug Safety Summit

Stamford, CT, September 16, 2010 – Synowledge LLC, a market leader in drug safety and pharmacovigilance services and related IT solutions for life sciences organizations of all sizes announced today that Dr. Jacinta Aniagolu Johnson, Director, Pharmacovigilance and Risk Management, will be representing Synowledge at Pacific Drug Safety Summit at San Francisco Airport Marriott, Burlingame, California, USA on 23rd-24th September 2010.

The Pacific Drug Safety Summit will provide half-day training sessions on key drug safety and pharmacovigilance practice areas. Attendees will have the opportunity to participate in networking breaks and interact with a diverse gathering of US and EU drug safety and pharmacovigilance practitioners, service providers, and vendors.

Conference Details: Pacific Drug Safety Summit

Date & Time: September 23-24, 2010, 8.30 am – 5.00pm Pacific Time

Location: San Francisco Airport Marriott, Burlingame, California, USA

Pre-Conference Tutorial #2: Risk Evaluation and Mitigation Strategies (REMS)

An Overview of Current Regulations and Approach to Documentation and Preparation
Speaker: Dr. Jacinta Aniagolu Johnson, Director, EU PV and Risk Management

Description: A full agenda of contemporary, cutting-edge pharmacovigilance topics from nine experienced speakers in the pharmacovigilance and risk management field.

Dr. Jacinta, along with Mark Loudon from Aris Global, will present an overview of current regulations and approaches to documentation and preparation. The goal will be to provide users with information about practical mechanisms at both the strategic and operational level to help demystify and apply proper risk management methods.

Topics include:

  • Practical Elements for Risk Management
  • FDAAA
  • Relationship between REMS and RiskMAPs
  • FDA REMS template
  • REMS contents
  • Highlights of the FDA draft REMS Guidance, and examples of FDA-approved proposed REMS

About Dr. Jacinta Aniagolu Johnson

Dr. Jacinta Aniagolu is a trained biomedical and clinical research scientist, an AE/ADR signal analysis and pharmacovigilance, risk management and drug safety surveillance subject matter expert. She has 17 years combined expertise and cross-functional knowledge in biomedical and clinical drug development research, drug safety surveillance, pharmacovigilance, and risk management. Currently, as the Director, Pharmacovigilance and Risk Management, at Synowledge, Dr. Aniagolu directs client Pharmacovigilance and Risk Management project activities. She provides leadership, guidance and subject matter expertise in the areas of Drug Safety and Pharmacovigilance, and medical/scientific affairs.

About Synowledge

Synowledge is a global provider of drug safety and pharmacovigilance services and related IT solutions to small, mid and large size pharmaceutical and biotechnology companies. Our comprehensive outsourcing solutions combine the unique strengths of both onshore and offshore services to meet all our clients’ needs. With more than 15 years of industry experience, our core team members have worked with leading pharmaceutical, biotech, medical device and health provider organizations. We have our headquarters located in Stamford CT, USA and additional offices in Bangalore, India and the United Kingdom. For more information, please visit www.synowledge.com.

###

Synowledge Announces 15 New Customer Wins Worldwide

LONDON — August 30, 2010 – Synowledge LLC, a market leader in drug safety and pharmacovigilance services and related IT solutions for life sciences organizations of all sized announced its largest customer win growth to-date. Synowledge signs 15 new customers in 2010 (including a fortune 100 company and a top 20 pharma company). These new accounts outline Synowledge’s accelerating growth in its customer base and revenues.

Synowledge’s proven ability to provide its customers with quality services is evident in this double digit customer account growth. Synowledge’s growth in customer wins was spurred by the expansion of its global customer base – as well as Synowledge’s excellent service to existing customers.

In the past one year, Synowledge has dramatically increased its customer base with a number of new customers, including a fortune 100 company and a top 20 pharma company across the globe. In addition, existing Synowledge customers continued to upgrade and expand their usage of Synowledge solutions. Synwoledge’s strategic direction and customer-focused approach continue to drive the company’s innovation and growth.

“Synowledge, backed by its strong expertise in drug safety, PV and IT solutions, continues to invest proactively in the strategic expansion of its solution suite. Our solutions continue to be chosen over those offered by some of the largest service providers in the industry,” said David Ingraham, Director, Marketing & Sales.

About Synowledge

Synowledge is a global provider of drug safety and pharmacovigilance services and related IT solutions to small, mid and large size pharmaceutical and biotechnology companies. Our comprehensive outsourcing solutions combine the unique strengths of both onshore and offshore services to meet all our clients’ needs. With more than 15 years of industry experience, our core team members have worked with leading pharmaceutical, biotech, medical device and health provider organizations. We have our headquarters located in Stamford CT, USA and additional offices in Bangalore, India and the United Kingdom. For more information, please visit www.synowledge.com.

###

Synowledge Continues Global Expansion with New Offices in UK and USA

LONDON — August 30, 2010 – Synowledge LLC, the market leader in drug safety and pharmacovigilance services and related IT solutions for life sciences organizations announced its inauguration of two new offices in Brentford, UK and Columbus OH, USA as part of its ongoing global growth strategy. These two new offices will act as strategic development centers and will also provide support services to Synowledge’s expanding client-base in the US and UK markets. The office addresses are given below:

UK Office Address:

Synowledge UK Limited

1000 Great West Road

Brentford, TW8 9HH

United Kingdom

USA Office Address:

1900 Polaris Parkway, Suite 450

Columbus, Ohio

43240

The decision to establish these two new offices in the US and UK is a result of the significant customer wins Synowledge has experienced in 2010. The expertise of Synowledge’s professionals and their ability to work closely with its customers as a trusted partner have resulted in significant growth in customer base and enhanced level of interest in our solutions.

The USA and UK region is a key market for Synowledge, and we recognize how important these two new facilities are for both our existing business initiatives and future strategic campaigns in the region. In addition to meeting current challenges for Synwoledge’s strategic growth, these two facilities will allow Synowledge to deliver superior sales and support to our customers and to the growing prospect base in the regions.

“We have seen a growing need from our clients in these two regions. Strengthening our presence in key regions around the globe is among a number of current programs we have launched to improve our customer service and build stronger relationships with our customers around the world.” said David Ingraham, Director, Marketing & Sales, “Since embarking on its worldwide strategic expansion plan in 2006, Synowledge is committed to deliver on technology innovation by continually improving our ability to service our current and new clients’ needs.”

About Synowledge

Synowledge is a global provider of drug safety and pharmacovigilance services and related IT solutions to small, mid and large size pharmaceutical and biotechnology companies. Our comprehensive outsourcing solutions combine the unique strengths of both onshore and offshore services to meet all our clients’ needs. With more than 15 years of industry experience, our core team members have worked with leading pharmaceutical, biotech, medical device and health provider organizations. We have our headquarters located in Stamford CT, USA and additional offices in Bangalore, India and the United Kingdom. For more information, please visit www.synowledge.com.

###